KELIOMICS, INC.

PORTLAND, OR · CIK 0001949231 · Biotech · Private

Human breast tissue culture platform that maintains viability ex vivo to generate patient-population-specific models of breast cancer subtypes

Grants
$399K
1 award
Sector median: 1
Raised
$250K
1 Form D · Oct 2022
48 months since last filing
Contracts
—
No federal contracts on record
Patents
1
0 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$250,000
Federal grantDepartment of Health and Human Services · Phase I · Engineering ex vivo breast tumors in human breast tissue to address racial disparities in HR-/ERBB2+ breast cancer$398,895
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1190BioVaxys Technology Corp.—$301K
1191Petri Bio LLC—$255K
1192PreveCeutical Medical Inc.—$254K
1193KELIOMICS, INC.—$250K
1194ELF ZONE, INC.——
1195Tengen Biomedical Co——
1196VICOLINE MEDICAL, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 2 related persons
  • Jason BourgeoisDirector · Executive Officer
  • Frank LauDirector · Executive Officer

Patents

USPTO · 0 granted of 1
  • Methods And Systems For Transportation And Culture Of Buoyant Tissueapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.